These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21320292)

  • 1. In vitro studies of dasatinib, its targets and predictors of sensitivity.
    Jilaveanu LB; Zito CR; Aziz SA; Chakraborty A; Davies MA; Camp RL; Rimm DL; Dudek A; Sznol M; Kluger HM
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):386-9. PubMed ID: 21320292
    [No Abstract]   [Full Text] [Related]  

  • 2. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
    Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
    Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.
    Morton JP; Karim SA; Graham K; Timpson P; Jamieson N; Athineos D; Doyle B; McKay C; Heung MY; Oien KA; Frame MC; Evans TR; Sansom OJ; Brunton VG
    Gastroenterology; 2010 Jul; 139(1):292-303. PubMed ID: 20303350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
    Rice L; Lepler S; Pampo C; Siemann DW
    Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
    Buettner R; Mesa T; Vultur A; Lee F; Jove R
    Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
    Ortiz R; Díaz J; Díaz-Valdivia N; Martínez S; Simón L; Contreras P; Lobos-González L; Guerrero S; Leyton L; Quest AFG
    Biochem Pharmacol; 2020 Jul; 177():113941. PubMed ID: 32240650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
    Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
    Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib: an anti-tumour agent via Src inhibition.
    Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
    Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib in solid tumors.
    Kim LC; Rix U; Haura EB
    Expert Opin Investig Drugs; 2010 Mar; 19(3):415-25. PubMed ID: 20113198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Src in prostate cancer.
    Fizazi K
    Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 trial of dasatinib in advanced melanoma.
    Kluger HM; Dudek AZ; McCann C; Ritacco J; Southard N; Jilaveanu LB; Molinaro A; Sznol M
    Cancer; 2011 May; 117(10):2202-8. PubMed ID: 21523734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.
    de Groot J; Milano V
    J Neurooncol; 2009 Nov; 95(2):151-163. PubMed ID: 19436954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib suppresses in vitro natural killer cell cytotoxicity.
    Blake SJ; Bruce Lyons A; Fraser CK; Hayball JD; Hughes TP
    Blood; 2008 Apr; 111(8):4415-6. PubMed ID: 18398058
    [No Abstract]   [Full Text] [Related]  

  • 15. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
    Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
    Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
    Ahluwalia MS; de Groot J; Liu WM; Gladson CL
    Cancer Lett; 2010 Dec; 298(2):139-49. PubMed ID: 20947248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
    Finn RS; Aleshin A; Dering J; Yang P; Ginther C; Desai A; Zhao D; von Euw E; Busuttil RW; Slamon DJ
    Hepatology; 2013 May; 57(5):1838-46. PubMed ID: 23299860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
    Johnson FM; Saigal B; Tran H; Donato NJ
    Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
    Finn RS; Bengala C; Ibrahim N; Roché H; Sparano J; Strauss LC; Fairchild J; Sy O; Goldstein LJ
    Clin Cancer Res; 2011 Nov; 17(21):6905-13. PubMed ID: 22028489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.